Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharvaris N.V.

14.82
-0.2700-1.79%
Pre-market: 13.80-1.0200-6.88%04:10 EDT
Volume:22.09K
Turnover:333.06K
Market Cap:807.59M
PE:-5.76
High:15.44
Open:15.10
Low:14.70
Close:15.09
Loading ...

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

TIPRANKS
·
18 Feb

Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)

TIPRANKS
·
10 Feb

Morgan Stanley Remains a Buy on Pharvaris (PHVS)

TIPRANKS
·
03 Feb

Why Pharvaris (PHVS) Is Advancing Today

Insider Monkey
·
01 Feb

Pharvaris (PHVS) Gets a Buy from JMP Securities

TIPRANKS
·
31 Jan

Analysts Offer Insights on Healthcare Companies: Stevanato Group (STVN), Galapagos (GLPG) and Pharvaris (PHVS)

TIPRANKS
·
27 Jan

Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?

Insider Monkey
·
23 Jan

Bank of America Securities Sticks to Their Sell Rating for Pharvaris (PHVS)

TIPRANKS
·
16 Jan

Pharvaris Sets 2025 Strategic Priorities in HAE and AAE Treatments

TIPRANKS
·
13 Jan

Pharvaris Outlines 2025 Strategic Priorities

THOMSON REUTERS
·
13 Jan

Pharvaris Nv - Estimates Cash Runway Into 3Q2026

THOMSON REUTERS
·
13 Jan

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)

TIPRANKS
·
02 Jan

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

TIPRANKS
·
23 Dec 2024

Pharvaris price target lowered to $46 from $50 at JMP Securities

TipRanks
·
06 Dec 2024

Pharvaris Reports Q3 2024 Progress and Financials

TIPRANKS
·
26 Nov 2024

Stock Track | Pharvaris N.V. Soars 5.94% on Analyst Optimism

Stock Track
·
22 Nov 2024

Morgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)

TIPRANKS
·
22 Nov 2024

Oppenheimer Remains a Buy on Pharvaris (PHVS)

TIPRANKS
·
14 Nov 2024

Pharvaris Q3 EPS $(0.85) Misses $(0.67) Estimate

Benzinga
·
14 Nov 2024

Pharvaris Advances in HAE Treatment with Strong Financials

TIPRANKS
·
14 Nov 2024